Pharma BD Deal Intelligence
The acquisition will give AstraZeneca access to a potential new treatment for COPD, currently in late-stage development, and inhaler and formulation technology…
AstraZeneca expressed strong interest in Pearl's triple combination paired with Symbicort's ICS, framing it as 'the Holy Grail in respiratory medicine' and a…
PINNACLE 1 and PINNACLE 2 Phase 3 trials of PT003 met primary endpoints in moderate-to-severe COPD, supporting NDA submission and validating the deal thesis…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
AstraZeneca to acquire Pearl for $560M upfront + up to $450M dev milestones + up to $140M sales milestones (total up to $1.15B); strengthens respiratory franchise via PT003/PT010 inhaled COPD combinations.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Pearl Therapeutics Inc. (this deal) | 2013 | $1.1B | 61 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2013 deals · AstraZeneca PLC deals · Respiratory deals